Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

Compare

1,626 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RCKT Analyst Ratings

Moderate Buy

8 Buy

6 Hold

1 Sell

Based on 15 analysts giving stock ratings to

Rocket

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RCKT Stock 12 Month Forecast

Average Price Target

$8.91

▲(171.65% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $8.91 with a high forecast of $19.00 and a low forecast of $2.00. The average price target represents a 171.65% change from the last price of $3.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","23":"$23","6.5":"$6.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.5,12,17.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,4.2215384615384615,5.453076923076923,6.684615384615385,7.916153846153846,9.147692307692306,10.37923076923077,11.61076923076923,12.842307692307692,14.073846153846153,15.305384615384614,16.536923076923074,17.768461538461537,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,3.4453846153846155,3.9007692307692308,4.3561538461538465,4.811538461538461,5.266923076923077,5.722307692307693,6.177692307692308,6.633076923076923,7.088461538461539,7.543846153846154,7.99923076923077,8.454615384615385,{"y":8.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.99,2.913846153846154,2.8376923076923077,2.7615384615384615,2.6853846153846157,2.6092307692307695,2.5330769230769232,2.456923076923077,2.3807692307692307,2.304615384615385,2.2284615384615387,2.1523076923076925,2.0761538461538462,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$8.91

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yun Zhong

Wedbush

$16

Buy

387.80%

Upside

Reiterated

08/28/25

Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Advancements in RP-A501 Study

Whitney Ijem

Canaccord Genuity

$10

Buy

204.88%

Upside

Reiterated

08/20/25

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT)

Geulah Livshits

Chardan Capital

$11→$12

Buy

265.85%

Upside

Reiterated

08/20/25

Rocket alignment with FDA 'sounds reasonable,' says ChardanRocket alignment with FDA 'sounds reasonable,' says Chardan

Cory Jubinville, PhD

LifeSci Capital

Buy

174.39%

Upside

Reiterated

08/20/25

Rocket Pharmaceuticals' RP-A501 Study Advances with FDA Approval and Enhanced Safety Measures, Justifying Buy RatingThis morning, Rocket Pharma (Nasdaq: RCKT) announced that the FDA lied the clinical hold on its pivotal Phase 2 study of RP-A501 for Danon disease, less than three months aer the hold was ﬁrst implemented. In May, Rocket voluntarily paused dosing, and the FDA subsequently placed a clinical hold on the program, aer a paent experienced capillary leak syndrome that progressed to an acute systemic infecon where the paent eventually died (NOTE HERE).

Jason Zemansky

Bank of America Securities

$4→$10

Buy

204.88%

Upside

Upgraded

08/20/25

Rocket Pharmaceuticals upgraded to Buy from Neutral at BofARocket Pharmaceuticals upgraded to Buy from Neutral at BofA

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/20/25

Analysts' Top Healthcare Picks: Rocket Pharmaceuticals (RCKT), Alcon (ALC)

Richard Law CFA

Goldman Sachs

Sell

-39.02%

Downside

Reiterated

08/20/25

Rocket Pharmaceuticals (RCKT) Receives a Sell from Goldman Sachs

Michael Ulz

Morgan Stanley

Hold

113.41%

Upside

Reiterated

08/20/25

Cautious Optimism for Rocket Pharmaceuticals Amid Adjusted RP-A501 Trial Protocol

Gil Blum

Needham

―

Hold

―

Reiterated

08/20/25

Cautious Optimism: Hold Rating on Rocket Pharmaceuticals Amid Resumed Phase II Study with Protocol Changes

Mani Foroohar

Leerink Partners

―

Hold

―

Reiterated

08/20/25

Hold Rating on Rocket Pharmaceuticals Amid Uncertainties in RP-A501 Study Resumption

Gavin Clark-Gartner

Evercore ISI

Hold

52.44%

Upside

Reiterated

08/11/25

Evercore ISI Sticks to Their Hold Rating for Rocket Pharmaceuticals (RCKT)

Andrew Tsai

Jefferies

$2.5→$3

Hold

-8.54%

Downside

Reiterated

08/08/25

Jefferies Sticks to Its Hold Rating for Rocket Pharmaceuticals (RCKT)Jefferies analyst Andrew Tsai raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $3.00 (from $2.50) while maintaining a Hold rating.

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

08/08/25

Rocket Pharmaceuticals: Strategic Shift Amidst Clinical Challenges and Promising Pipeline Developments

Greg Harrison

Scotiabank

$19

Buy

479.27%

Upside

Reiterated

07/25/25

Scotiabank Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)

Ashwani Verma

UBS

$12→$5

Buy

52.44%

Upside

Reiterated

06/17/25

Rocket Pharmaceuticals price target lowered to $5 from $12 at UBSRocket Pharmaceuticals price target lowered to $5 from $12 at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yun Zhong

Wedbush

$16

Buy

387.80%

Upside

Reiterated

08/28/25

Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Advancements in RP-A501 Study

Whitney Ijem

Canaccord Genuity

$10

Buy

204.88%

Upside

Reiterated

08/20/25

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT)

Geulah Livshits

Chardan Capital

$11→$12

Buy

265.85%

Upside

Reiterated

08/20/25

Rocket alignment with FDA 'sounds reasonable,' says ChardanRocket alignment with FDA 'sounds reasonable,' says Chardan

Cory Jubinville, PhD

LifeSci Capital

Buy

174.39%

Upside

Reiterated

08/20/25

Jason Zemansky

Bank of America Securities

$4→$10

Buy

204.88%

Upside

Upgraded

08/20/25

Rocket Pharmaceuticals upgraded to Buy from Neutral at BofARocket Pharmaceuticals upgraded to Buy from Neutral at BofA

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/20/25

Analysts' Top Healthcare Picks: Rocket Pharmaceuticals (RCKT), Alcon (ALC)

Richard Law CFA

Goldman Sachs

Sell

-39.02%

Downside

Reiterated

08/20/25

Rocket Pharmaceuticals (RCKT) Receives a Sell from Goldman Sachs

Michael Ulz

Morgan Stanley

Hold

113.41%

Upside

Reiterated

08/20/25

Cautious Optimism for Rocket Pharmaceuticals Amid Adjusted RP-A501 Trial Protocol

Gil Blum

Needham

―

Hold

―

Reiterated

08/20/25

Cautious Optimism: Hold Rating on Rocket Pharmaceuticals Amid Resumed Phase II Study with Protocol Changes

Mani Foroohar

Leerink Partners

―

Hold

―

Reiterated

08/20/25

Hold Rating on Rocket Pharmaceuticals Amid Uncertainties in RP-A501 Study Resumption

Gavin Clark-Gartner

Evercore ISI

Hold

52.44%

Upside

Reiterated

08/11/25

Evercore ISI Sticks to Their Hold Rating for Rocket Pharmaceuticals (RCKT)

Andrew Tsai

Jefferies

$2.5→$3

Hold

-8.54%

Downside

Reiterated

08/08/25

Tyler Van Buren

TD Cowen

―

Hold

―

Reiterated

08/08/25

Rocket Pharmaceuticals: Strategic Shift Amidst Clinical Challenges and Promising Pipeline Developments

Greg Harrison

Scotiabank

$19

Buy

479.27%

Upside

Reiterated

07/25/25

Scotiabank Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)

Ashwani Verma

UBS

$12→$5

Buy

52.44%

Upside

Reiterated

06/17/25

Rocket Pharmaceuticals price target lowered to $5 from $12 at UBSRocket Pharmaceuticals price target lowered to $5 from $12 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rocket Pharmaceuticals

1 Month

xxx

Success Rate

16/26 ratings generated profit

Average Return

+6.42%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +6.42% per trade.

3 Months

xxx

Success Rate

16/26 ratings generated profit

Average Return

+13.69%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +13.69% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

16/26 ratings generated profit

Average Return

+19.78%

reiterated a buy rating 20 days ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +19.78% per trade.

2 Years

xxx

Success Rate

8/26 ratings generated profit

Average Return

-19.47%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -19.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCKT Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RCKT has received 18 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. RCKT average Analyst price target in the past 3 months is 8.91.

Each month's total comprises the sum of three months' worth of ratings.

RCKT Financial Forecast

RCKT Earnings Forecast

Next quarter’s earnings estimate for RCKT is -$0.48 with a range of -$0.60 to -$0.37. The previous quarter’s EPS was -$0.62. RCKT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.84% of the time in the same period. In the last calendar year RCKT has Outperformed its overall industry.

No data currently available

RCKT Sales Forecast

Next quarter’s sales forecast for RCKT is $359.00K with a range of $0.00 to $2.50M. The previous quarter’s sales results were $0.00. RCKT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.74% of the time in the same period. In the last calendar year RCKT has Preformed in-line its overall industry.

RCKT Stock Forecast FAQ

What is RCKT’s average 12-month price target, according to analysts?

Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is 8.91.

What is RCKT’s upside potential, based on the analysts’ average price target?

Rocket Pharmaceuticals has 171.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RCKT a Buy, Sell or Hold?

Rocket Pharmaceuticals has a consensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 1 sell ratings.

What is Rocket Pharmaceuticals’s price target?

The average price target for Rocket Pharmaceuticals is 8.91. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $2.00. The average price target represents 171.65% Increase from the current price of $3.28.

What do analysts say about Rocket Pharmaceuticals?

Rocket Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of RCKT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

RCKT Analyst Ratings

RCKT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rocket Pharmaceuticals

RCKT Analyst Recommendation Trends

RCKT Financial Forecast

RCKT Earnings Forecast

RCKT Sales Forecast

RCKT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts